titled "SGI-1252: A Potent Small Molecule JAK2 Inhibitor," Dr.
Steven Warner, Manager of Discovery Biology, highlighted how
SuperGen scientists used the Company's CLIMB technology to identify
SGI-1252 as a possible JAK2 inhibitor. Dr. Warner presented data
indicating that SGI-1252 selectively inhibits wildtype and mutant
JAK2 activity in cancer cell lines, resulting in inhibition of STAT5
phosphorylation as well as a reduction in Bcl-XL expression.
SGI-1252 was also shown to inhibit tumor growth in mouse xenograft
models. Pharmacokinetic studies suggest that SGI-1252 is orally
-- July 2008: The Company commented on the preliminary data from a Phase
3 trial, initiated in 2002, comparing Dacogen to best supportive care
(BSC) in elderly patients with myelodysplastic syndromes (MDS). The
data did not demonstrate a statistically significant advantage of
Dacogen treatment on median survival compared to BSC, the primary
endpoint of the study. However, response rates were similar to those
observed in other clinical trials of Dacogen in patients with MDS. The
trial, conducted by the European Organisation for Research and
Treatment of Cancer (EORTC), administered Dacogen on a three-day dosing
schedule in which the number of treatment cycles was limited. MDS is a
potentially life-threatening group of bone marrow diseases that limit
the production of functional blood cells. Subsequent to database lock
and the completion of data analysis, comprehensive results of the
study, including secondary efficacy endpoints and safety data, will be
presented by EORTC at an upcoming scientific forum.
Conference Call Information
SuperGen will ho
|SOURCE SuperGen, Inc.|
Copyright©2008 PR Newswire.
All rights reserved